Reuters logo
BRIEF-Valeant Pharmaceuticals reports Q1 GAAP earnings per share $1.79
2017年5月9日 / 上午11点09分 / 6 个月前

BRIEF-Valeant Pharmaceuticals reports Q1 GAAP earnings per share $1.79

May 9 (Reuters) - Valeant Pharmaceuticals International Inc :

* Valeant - reduced debt by $1.3 billion in quarter

* Valeant announces first quarter 2017 results and raises full year adjusted EBITDA guidance range

* Q1 revenue $2.109 billion versus I/B/E/S view $2.18 billion

* Q1 GAAP earnings per share $1.79

* Q1 earnings per share view $0.87 -- Thomson Reuters I/B/E/S

* Valeant - sees 2017 full year adjusted EBITDA (non-GAAP) in range of $3.60 - $3.75 billion from $3.55 - $3.70 billion

* Valeant - total long term debt as of March 31, 2017 was $28,544 million versus. $29,846 million as of Dec. 31, 2016 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below